Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 7/20 | 0.53 |
| ▸ | OPRM1 | P35372 | 6/20 | 0.46 |
| ▸ | OPRD1 | P41143 | 6/20 | 0.46 |
| ▸ | OPRK1 | P41145 | 5/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18408187 | 1.00 | HSD11B1 (0.53) | HSD11B1OPRM1OPRD1OPRK1 | |
| SCHEMBL18259037 | 1.00 | HSD11B1 (0.53) | HSD11B1OPRM1OPRD1OPRK1 | |
| SCHEMBL12881650 | 1.00 | HSD11B1 (0.53) | HSD11B1OPRM1OPRD1OPRK1 | |
| SCHEMBL1299614 | 1.00 | HSD11B1 (0.53) | HSD11B1OPRM1OPRD1OPRK1 | |
| SCHEMBL1207689 | 1.00 | HSD11B1 (0.53) | HSD11B1OPRM1OPRD1OPRK1 | |
| SCHEMBL18407996 | 0.89 | HSD11B1 (0.55) | HSD11B1OPRM1OPRD1OPRK1 | |
| SCHEMBL1207406 | 0.89 | HSD11B1 (0.55) | HSD11B1OPRM1OPRD1OPRK1 | |
| SCHEMBL1207527 | 0.82 | OPRD1 (0.60) | HSD11B1OPRM1OPRD1OPRK1 | |
| SCHEMBL18408185 | 0.82 | OPRD1 (0.60) | HSD11B1OPRM1OPRD1OPRK1 | |
| SCHEMBL16451322 | 0.82 | HSD11B1 (0.67) | HSD11B1OPRM1OPRD1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12257249-B2 | Methods for treating depressive symptoms | ALKERMES PHARMA IRELAND LIMITED (IE) | 2025-03-25 | — | — | US | disclosed |
| US-20230158017-A1 | METHODS FOR TREATING DEPRESSIVE SYMPTOMS | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2023-05-25 | — | — | US | disclosed |
| US-11534436-B2 | Methods for treating depressive symptoms | ALKERMES PHARMA IRELAND LIMITED (IE) | 2022-12-27 | — | — | US | disclosed |
| US-20210000818-A1 | METHODS FOR TREATING DEPRESSIVE SYMPTOMS | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2021-01-07 | — | — | US | disclosed |
| US-10752592-B2 | Morphan and morphinan analogues, and methods of use | ALKERMES PHARMA IRELAND LIMITED (IE) | 2020-08-25 | — | — | US | disclosed |
| US-10736890-B2 | Methods for treating depressive symptoms | ALKERMES PHARMA IRELAND LIMITED (IE) | 2020-08-11 | — | — | US | disclosed |
| EP-3004114-B1 | MORPHAN AND MORPHINAN ANALOGUES, AND METHODS OF USE | ALKERMES PHARMA IRELAND LTD (IE) | 2019-12-25 | — | — | EP | disclosed |
| US-20190218185-A1 | Morphan And Morphinan Analogues, And Methods Of Use | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2019-07-18 | — | — | US | disclosed |
| US-20190167666-A1 | METHODS FOR TREATING DEPRESSIVE SYMPTOMS | ALKERMES PHARMA IRELAND LIMITED (IE) | 2019-06-06 | — | — | US | disclosed |
| US-10287250-B2 | Morphan and morphinan analogues, and methods of use | ALKERMES PHARMA IRELAND LIMITED (IE) | 2019-05-14 | — | — | US | disclosed |
| US-20180016237-A1 | Morphan And Morphinan Analogues, And Methods Of Use | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2018-01-18 | — | — | US | disclosed |
| US-20170216279-A1 | METHODS FOR TREATING DEPRESSIVE SYMPTOMS | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2017-08-03 | — | — | US | disclosed |
| US-9682936-B2 | Morphan and morphinan analogues, and methods of use | ALKERMES PHARMA IRELAND LIMITED (IE) | 2017-06-20 | — | — | US | disclosed |
| US-9656961-B2 | Methods for treating depressive symptoms | ALKERMES PHARMA IRELAND LIMITED (IE) | 2017-05-23 | — | — | US | disclosed |
| US-20160326119-A1 | MORPHAN AND MORPHINAN ANALOGUES, AND METHODS OF USE | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2016-11-10 | — | — | US | disclosed |
| US-9416137-B2 | Morphan and morphinan analogues, and methods of use | ALKERMES PHARMA IRELAND LIMITED (IE) | 2016-08-16 | — | — | US | disclosed |
| US-20150376197-A1 | MORPHAN AND MORPHINAN ANALOGUES, AND METHODS OF USE | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2015-12-31 | — | — | US | disclosed |
| US-9133125-B2 | Morphan and morphinan analogues, and methods of use | ALKERMES PHARMA IRELAND LIMITED (IE) | 2015-09-15 | — | — | US | disclosed |
| US-20150072971-A1 | Methods for Treating Depressive Symptoms | ALKERMES PHARMA IRELAND LIMITED (IE) | 2015-03-12 | — | — | US | disclosed |
| US-20150045384-A1 | Morphan and Morphinan Analogues, and Methods of Use | ALKERMES PHARMA IRELAND LIMITED (IE) | 2015-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190167666-A1 | METHODS FOR TREATING DEPRESSIVE SYMPTOMS | OPRM1, OPRL1, OPRK1 | HSD11B1 555/4885OPRM1 1/4885OPRD1 4/4885 |
| US-12257249-B2 | Methods for treating depressive symptoms | OPRM1, OPRL1, OPRK1 | HSD11B1 555/4885OPRM1 1/4885OPRD1 4/4885 |
| US-20210000818-A1 | METHODS FOR TREATING DEPRESSIVE SYMPTOMS | OPRM1, OPRL1, OPRK1 | HSD11B1 555/4885OPRM1 1/4885OPRD1 4/4885 |
| US-10287250-B2 | Morphan and morphinan analogues, and methods of use | MTPN, UTRN, FSCN1 | HSD11B1 1707/4885OPRM1 159/4885OPRD1 642/4885 |
| US-20180016237-A1 | Morphan And Morphinan Analogues, And Methods Of Use | MTPN, UTRN, FSCN1 | HSD11B1 1710/4885OPRM1 159/4885OPRD1 666/4885 |
| US-20150072971-A1 | Methods for Treating Depressive Symptoms | OPRM1, OPRL1, OPRK1 | HSD11B1 555/4885OPRM1 1/4885OPRD1 4/4885 |
| US-20230158017-A1 | METHODS FOR TREATING DEPRESSIVE SYMPTOMS | OPRM1, OPRL1, OPRK1 | HSD11B1 555/4885OPRM1 1/4885OPRD1 4/4885 |
| US-20150376197-A1 | MORPHAN AND MORPHINAN ANALOGUES, AND METHODS OF USE | MTPN, UTRN, FSCN1 | HSD11B1 1710/4885OPRM1 159/4885OPRD1 666/4885 |
| US-11534436-B2 | Methods for treating depressive symptoms | OPRM1, OPRL1, OPRK1 | HSD11B1 555/4885OPRM1 1/4885OPRD1 4/4885 |
| US-20150045384-A1 | Morphan and Morphinan Analogues, and Methods of Use | MTPN, UTRN, FSCN1 | HSD11B1 1710/4885OPRM1 159/4885OPRD1 666/4885 |
| US-20160326119-A1 | MORPHAN AND MORPHINAN ANALOGUES, AND METHODS OF USE | MTPN, UTRN, FSCN1 | HSD11B1 1710/4885OPRM1 159/4885OPRD1 666/4885 |
| US-10736890-B2 | Methods for treating depressive symptoms | OPRM1, OPRL1, OPRK1 | HSD11B1 555/4885OPRM1 1/4885OPRD1 4/4885 |
| US-10752592-B2 | Morphan and morphinan analogues, and methods of use | MTPN, UTRN, FSCN1 | HSD11B1 1710/4885OPRM1 159/4885OPRD1 666/4885 |
| US-20170216279-A1 | METHODS FOR TREATING DEPRESSIVE SYMPTOMS | OPRM1, OPRL1, OPRK1 | HSD11B1 555/4885OPRM1 1/4885OPRD1 4/4885 |
| US-20190218185-A1 | Morphan And Morphinan Analogues, And Methods Of Use | MTPN, UTRN, FSCN1 | HSD11B1 1710/4885OPRM1 159/4885OPRD1 666/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.